


Pending Claims

A complete list of all claims under examination is set out below. Please amend claims 11, 16, 31, 32, and 51.

1 - 10. (cancelled).

11. (Currently amended) ~~A~~ The compound of claim 50 of the formula:



wherein

R₁₁ is C₅-C₁₈ alkyl, C₅-C₁₈ alkenyl, C₅-C₁₈ alkynyl, C₅-C₁₈ alkoxy, C₁-C₁₀ alkyl(C₅-C₆ aryl)R₂₀, C₁-C₁₀ alkyl(C₅-C₆ heteroaryl)R₂₀, C₁-C₁₀ alkyl(C₅-C₆ cycloalkyl)R₂₀, C₁-C₁₀ alkoxy(C₅-C₆ aryl)R₂₀, C₁-C₁₀ alkoxy(C₅-C₆ heteroaryl)R₂₀ or C₁-C₁₀ alkoxy(C₅-C₆ cycloalkyl)R₂₀;

wherein R₂₀ is H or C₁-C₁₀ alkyl;

p and q are integers independently ranging from 1 to 10;

R₂₉ is H, halo, C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, or C₁-C₁₂ alkoxy;

R₇ and R₈ are independently is O, S, or NR₂₆, or N;

R₈ is O, S, or NR₂₆;


wherein R₂₆ is H, F or C₁-C₄ alkyl;

R₂₅ is CH₃;

R₃ is hydrogen, C₁-C₄ alkyl, (C₁-C₄ alkyl)OH, or (C₁-C₄ alkyl)NH₂;

R₁₅ is













USSN: 10/578,216
Group Art Unit: 1626
Docket No.: 198P00944USWO



wherein R₁₂ is O or S;

X is O, S, CH₂, CHO_H, CHF, CF₂, or $\text{--C}=\text{O}$;

R₃₀ and R₃₁ are each independently C₁-C₂ alkoxy,



R₂₃ is H, F, OH, C₁-C₄ alkyl, CO₂H or (C₁-C₄ alkyl)OH;


R₂₄ is H, F, C₁-C₄ alkyl or PO₃H₂; or

R₂₃ together with R₂₄ and the carbon to which they are attached form a carbonyl group; and

y and m are integers independently ranging from 0 to 4; or


a pharmaceutically acceptable salt or tautomer thereof.

12. (previously presented) The compound of claim 11 wherein
m is 0;
y is 0 or 1;
 R_{23} and R_{24} are independently H or F.
 13. (previously presented) The compound of claim 11 wherein R_3 is C_1 - C_3 alkyl or (C_1 - C_4 alkyl)OH; and
 R_8 is CH.
 14. (previously presented) The compound of claim 12 wherein
 R_{11} is C_5 - C_{18} alkyl, C_5 - C_{18} alkenyl, C_5 - C_{18} alkynyl, or C_5 - C_{18} alkoxy and
 R_{29} is H, halo or C_1 - C_{12} alkyl; or
a pharmaceutically acceptable salt or tautomer thereof.
 15. (previously presented) The compound of claim 12 wherein
y is 0; and
 R_{15} is represented by the structure



wherein X is CH₂, CHOH, CHF, CF₂, or $\text{--C}=\text{O}$.


16. (Currently amended) The compound of claim 11 or 50 of the formula:




wherein R₁₁ is C₅-C₁₈ alkyl or C₅-C₁₈ alkenyl; and
R₈ is N, or S;
or a pharmaceutically acceptable salt or tautomer thereof.

17. (cancelled)


18. (previously presented) The compound of claim 16 wherein R₁₁ is C₅-C₉ alkyl;
R₁₅ is



wherein X is O, CH₂ or CHF;
R₃₀ and R₃₁ are independently




USSN: 10/578,216
Group Art Unit: 1626
Docket No.: 198P00944USWO



and R₃ is CH₃.

19. - 21. (cancelled)

22. (previously presented) The compound of claim 51 of the formula:




23. (previously presented) The compound of claim 22 wherein R₃ is C₁-C₄ alkyl or (C₁-C₄ alkyl)OH;

R₈ is O, S, or N;

R₂₃ is H or F; and

R₁₅ is represented by the structure




wherein X is O, CH₂, CHO, CHF, CF₂ or $\text{--C}=\text{O}$.

24. (previously presented) The compound of claim 53 wherein X is O.

25. (previously presented) The compound of claim 53 wherein X is CH₂, CHF or CF₂.


USSN: 10/578,216
Group Art Unit: 1626
Docket No.: 198P00944USWO

26. (previously presented) The compound of claim 53 wherein R₃₀ and R₃₁ are the same and are



27. (original) The compound of claim 25 wherein R₈ is N.

28. (previously presented) The compound of claim 25 of the formula:



wherein R₁₁ is H, C₅-C₁₈ alkyl, C₅-C₁₈ alkenyl, C₅-C₁₈ alkynyl, or C₅-C₁₈ alkoxy;


R₃ is CH₃; and

R₂₉ is H, C₁-C₄ alkyl.

29. (previously presented) The compound of claim 28 wherein R₁₁ is C₅-C₁₈ alkyl, or C₅-C₁₈ alkenyl; and R₂₉ H, or C₁-C₄ alkyl.

30. (previously presented) The compound of claim 28 wherein R₁₁ is C₅-C₁₈ alkyl or C₅-C₁₈ alkenyl; and R₂₉ is H.

31. (Currently amended) A pharmaceutical composition comprising a compound of the formula:



wherein

R₁₁ is C₅-C₁₈ alkyl, C₅-C₁₈ alkenyl, C₅-C₁₈ alkynyl, C₅-C₁₈ alkoxy, C₁-C₁₀ alkyl(C₅-C₁₀ aryl)R₂₀, C₁-C₁₀ alkyl(C₅-C₁₀ heteroaryl)R₂₀, C₁-C₁₀ alkyl(C₅-C₁₀ cycloalkyl)R₂₀, C₁-C₁₀ alkoxy(C₅-C₁₀ aryl)R₂₀, C₁-C₁₀ alkoxy(C₅-C₁₀ heteroaryl)R₂₀ or C₁-C₁₀ alkoxy(C₅-C₁₀ cycloalkyl)R₂₀;

wherein R₂₀ is H or C₁-C₁₀ alkyl;

R₂₉ is H, halo, C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, or C₁-C₁₂ alkoxy;

R₃ is H, C₁-C₆ alkyl, (C₁-C₄ alkyl)OH, or (C₁-C₄ alkyl)NH₂;

R₂₃ is H, F, CO₂H, OH, C₁-C₆alkyl C₁-C₄alkyl, or (C₁-C₄ alkyl)OH, or (C₁-C₄ alkyl)NH₂;

R₂₄ is H, F, C₁-C₄alkyl or PO₃H₂; or

R₂₃ together with R₂₄ and the carbon to which they are attached form a carbonyl group;

R₇ and R₈ are independently is O, S, or NR₂₆, or N;

R₈ is O, S, or NR₂₆;


wherein R₂₆ is H, F or C₁-C₄ alkyl;

R₂₅ is CH CR₂₆;


wherein R₂₆ is H, F or C₁-C₄ alkyl;

R₁₅ is


USSN: 10/578,216
Group Art Unit: 1626
Docket No.: 198P00944USWO



wherein R₁₂ is O, NH or S;




each R₃₀ is independently and each R₃₁ is independently C₁-C₂ alkoxy,



y and m are integers independently ranging from 0 to 4;


p and q are integers independently ranging from 1 to 10; or
a pharmaceutically acceptable salt or tautomer thereof;
and a pharmaceutically acceptable carrier.

32. (currently amended) The composition of claim 31 comprising a compound of the formula:



wherein R₁₁ is C₅-C₁₈ alkyl, C₅-C₁₈ alkenyl, C₅-C₁₈ alkynyl, or C₅-C₁₈ alkoxy;
wherein p and q are integers independently ranging from 1 to 10;

Q is



wherein R₇ and R₈ are independently is O, S, or NR₂₆, or N;

R₈ is O, S, or NR₂₆;

wherein R₂₆ is H, F or C₁-C₄ alkyl;


R₂₅ is CH CR₂₆; and

R₂₆ is H, F or C₁-C₄ alkyl;

R₃ is H, C₁-C₄ alkyl or (C₁-C₄ alkyl)OH;

R₂₃ is H, F or C₁-C₄ alkyl; and

R₁₅ is represented by the structure




wherein R₁₂ is O or S;

X is O, S, CH₂, CHO_H, CHF, CF₂, or $\text{--}\overset{\text{O}}{\underset{\text{C}}{\text{=}}}\text{--}$;


R₃₀ and R₃₁ are independently C₁-C₂ alkoxy,

USSN: 10/578,216
Group Art Unit: 1626
Docket No.: 198P00944USWO



or a pharmaceutically acceptable salt or tautomer thereof; and
a pharmaceutically acceptable carrier.

33. (previously presented) The composition of claim 32 wherein R₂₃ is H or F; and R₁₅ is




wherein X is O, CH₂, CHO_H, CHF, CF₂, or $\text{--}\overset{\text{O}}{\underset{\text{C}^--}{\text{C}}}\text{--}$.

34. (cancelled).

35. (previously presented) The composition of claim 54 wherein
X is CH₂, CF₂ or CHF; and
R₃₀ and R₃₁ are independently C₁-C₂ alkoxy,


USSN: 10/578,216
Group Art Unit: 1626
Docket No.: 198P00944USWO



36. - 49. (cancelled)


50. (cancelled)

51. (Currently amended) The compound of claim 11 50 of the formula



wherein R_{11} is C_5-C_{18} alkyl, C_5-C_{18} alkenyl, C_5-C_{18} alkynyl, or C_5-C_{18} alkoxy;


R_{15} is



wherein X is O , CH_2 , $CHOH$, CHF , CF_2 , or $\begin{array}{c} O \\ || \\ -C- \end{array}$;

R_{30} and R_{31} are independently C_1-C_2 alkoxy,


USSN: 10/578,216
 Group Art Unit: 1626
 Docket No.: 198P00944USWO



wherein p and q are integers independently ranging from 1 to 10;

R_{29} is H, C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl or C₂-C₁₀ alkynyl;


Q is



m is 0; and

R_{23} is H or F.

52. (previously presented) The compound of claim 51 of the formula:




USSN: 10/578,216
Group Art Unit: 1626
Docket No.: 198P00944USWO



R₁₂ is O; and X is O, CH₂, CHOH, CHF, CF₂, and $\text{--C}=\text{O}$.

53. (previously presented) The compound of claim 23 wherein X is O, CH₂, CHF or CF₂.

54. (previously presented) The composition of claim 33 wherein Q is



55. (previously presented) The composition of claim 35 wherein Q is

